HALTING PANCREATIC CANCER IS URGENT:
INCREASE FEDERAL FUNDING FOR LIFESAVING RESEARCH

PANCREATIC CANCER NUMBERS DON’T LIE

1. It is one of the deadliest major cancers with the lowest survival rate at just 9 percent.¹

2. It is expected to rise to the 2nd leading cause of cancer-related death in the U.S. around 2020.²

3. It is currently the 3rd leading cause of cancer-related death in the U.S.¹

No early detection tests for pancreatic cancer exist and few effective treatment options are available.

CONGRESSIONAL ACTION IS NEEDED TO IMPROVE OUTCOMES

The pancreatic cancer community is grateful for congressional support that has increased research funding through the National Institutes of Health (NIH) and the National Cancer Institute (NCI). However, pancreatic cancer’s statistics tell us it’s not enough. (See chart.)

Innovative discoveries are being made in the lab due to the increases in research funding, but with extremely limited treatment options and no early detection method, additional funding and focused efforts are urgently needed to quickly advance these discoveries into meaningful solutions for patients and their families.

“When we all focus our resources, talents and time on a common issue, even a problem as devastating as this insidious disease can be overcome.”
—Eight-Year Pancreatic Cancer Survivor

IMPACT OF NIH FUNDING

Eighty percent of all pancreatic cancer research funding is provided via federal sources, most of it through the National Institutes of Health (NIH). This funding has resulted in basic understanding about differences between pancreatic cancer and healthy cells, which is paving the way toward early detection and treatments.

2016 NCI Annual Funding - Top Four Cancer Killers³

THE PANCREATIC CANCER ACTION NETWORK URGES THE 116TH CONGRESS TO MAKE MORE MOMENTS MATTER BY:

- Ensuring that lifesaving medical research can continue by funding the NIH at $41.6 billion for FY 2020, including $6.5 billion for the NCI.
- Making the nation’s deadliest cancer a priority by creating a dedicated pancreatic cancer research program within the Department of Defense’s (DoD) Congressionally Directed Medical Research Program (CDMRP).
- Monitoring and supporting the implementation of the Recalcitrant Cancer Research Act – ensuring the updates to Congress include critical next steps and recommendations to continue to advance the field of pancreatic cancer research.
- Joining the Congressional Caucus on the Deadliest Cancers to support and raise awareness about the nation’s deadliest cancers.